Development of tailor made peptide vaccines for renal cell carcinoma

我们一直致力于开发新的mhc - i类限制性肽疫苗，用于五个独立的治疗靶点，并已确定了一个重要的候选EPORxx。我们正在准备申请这种特殊肽疫苗的专利。我们还对18例弥散性肾细胞癌患者进行了VEGFR1肽疫苗的i /II期临床研究，显示了疫苗接种治疗的安全性和有效性。

e have been working on the development of new MHC-class-I restricted peptide vaccines for five independent therapeutic targets and have identified a significant candidate EPORxx. We are preparing the application of a patent for this particular peptide vaccine. We also carried out phase-I/II clinical study with VEGFR1 peptide vaccines for 18 patients with disseminated renal cell carcinoma, and showed the safty and efficacy of the vaccination treatment.